血液肿瘤α粒子核素治疗进展  

Progress of nuclide targetedα-particle therapy for blood tumors

作　　者：霍善棋 王瑾 张贝 曹凯[1] 孙少华[1] 陈成[1] 刘春艳[1] 苏是苍[1] Huo Shanqi;Wang Jin;Zhang Bei;Cao Kai;Sun Shaohua;Chen Cheng;Liu Chunyan;Su Shicang(Department of Nuclear Medicine,Jingzhou Central Hospital of Yangtze University,Jingzhou 434020,China)

机构地区：[1]长江大学附属荆州医院核医学科,荆州434020

出　　处：《中华核医学与分子影像杂志》2024年第9期564-568,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：血液肿瘤的发病率越来越高, 除了传统的放化疗外, 近年来随着核医学技术和核素的发展, 核素治疗在血液肿瘤的治疗中发挥着越来越重要的作用。目前, 血液肿瘤的核素治疗研究主要集中在急性髓性白血病(AML), 然而在其他血液肿瘤中也取得了不错的进展。^(213)Bi及^(225)Ac标记的单克隆抗体在血液肿瘤中取得了良好效果, ^(225)Ac克服了^(213)Bi的短半衰期和运输、保存的问题, 但是α粒子的临床使用仍然有许多问题需要解决。该文对血液系统的α粒子核素治疗进展进行综述, 以期为血液肿瘤治疗提供更广阔的思路。The incidence of blood tumors is getting higher and higher.In addition to traditional chemoradiotherapy,in recent years,with the development of nuclear medicine technology and nuclide,nuclide therapy is playing an increasingly important role in the treatment of blood tumors.At present,the main research on the treatment of blood tumors focuses on acute myeloid leukemia(AML),but progress has also been made in other blood tumors.^(213)Bi and ^(225)Ac-labeled monoclonal antibodies have achieved good results in blood tumors.^(225)Ac has overcome the short half-life of ^(213)Bi and the problems of transportation and preservation.However,there are still many problems to be solved in the clinical use ofαparticles.This article reviews the progress ofα-particle therapy in blood system,in order to provide a broader idea for the treatment of blood tumors.

关 键 词：血液肿瘤 放射疗法 Α粒子 发展趋势 

分 类 号：R733[医药卫生—肿瘤]